{"id":"ati-50002-topical-solution","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"headache"},{"rate":"5-10%","effect":"nausea"},{"rate":"5-10%","effect":"fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108694","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The JAK pathway is involved in the regulation of immune responses, and ATI-50002 is thought to modulate this pathway to treat psoriasis. By inhibiting the JAK pathway, ATI-50002 may help reduce inflammation and slow disease progression.","oneSentence":"ATI-50002 topical solution is a small molecule that targets the Janus kinase (JAK) pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:53.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT03495817","phase":"PHASE2","title":"A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-03-22","conditions":"Androgenetic Alopecia","enrollment":31},{"nctId":"NCT03468855","phase":"PHASE2","title":"A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-03-19","conditions":"Vitiligo","enrollment":34},{"nctId":"NCT03315689","phase":"PHASE2","title":"Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2017-12-14","conditions":"Alopecia Universalis (AU), Alopecia Totalis (AT)","enrollment":11},{"nctId":"NCT03354637","phase":"PHASE2","title":"A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata","status":"TERMINATED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2017-11-29","conditions":"Alopecia Areata","enrollment":129},{"nctId":"NCT03551821","phase":"PHASE2","title":"Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-04-11","conditions":"Alopecia Areata, Alopecia Totalis, Alopecia Universalis","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ATI-50002 topical solution","genericName":"ATI-50002 topical solution","companyName":"Aclaris Therapeutics, Inc.","companyId":"aclaris-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATI-50002 topical solution is a small molecule that targets the Janus kinase (JAK) pathway. Used for Moderate to severe plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}